Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $358000.0.

  • Madrigal Pharmaceuticals' Depreciation & Amortization (CF) rose 2013.42% to $358000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 6880.0%. This contributed to the annual value of $1.1 million for FY2024, which is 10796.96% up from last year.
  • Madrigal Pharmaceuticals' Depreciation & Amortization (CF) amounted to $358000.0 in Q3 2025, which was up 2013.42% from $377000.0 recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $379000.0 in Q1 2025 and a low of $89000.0 during Q2 2021
  • In the last 5 years, Madrigal Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $129000.0 in 2022 and averaged $189947.4.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Depreciation & Amortization (CF) crashed by 2260.87% in 2021 and then surged by 15563.38% in 2024.
  • Quarter analysis of 5 years shows Madrigal Pharmaceuticals' Depreciation & Amortization (CF) stood at $106000.0 in 2021, then increased by 21.7% to $129000.0 in 2022, then grew by 10.08% to $142000.0 in 2023, then surged by 155.63% to $363000.0 in 2024, then fell by 1.38% to $358000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $358000.0 in Q3 2025, compared to $377000.0 in Q2 2025 and $379000.0 in Q1 2025.